In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Biomedical Inc.

Division of Sumitomo Chemical Co.
www.bostonbiomedical.com

Latest From Boston Biomedical Inc.

Will 'Vant' Deal Really Fulfill Dainippon's Needs?

Sumitomo Dainippon's planned $3bn deal with Roivant goes some way to fulfilling the Japanese firm's strategic needs, but investors appear cool and questions remain.

Business Strategies Deals

$3bn Roivant Deal To Fill Holes At Dainippon

Facing looming expiries for its top product, Japan’s Sumitomo Dainippon is planning to acquire multiple "vant" companies and their portfolios of clinical stage assets from Roivant, in a move to address mid-term challenges to revenues and following recent late-stage development failures.

M & A Business Strategies

M&A A Major Pillar Of Sumitomo Dainippon's New Mid-Term Plan

Mid-size Japanese player Sumitomo Dainippon sets aside billions for potential M&A deals under a new business plan designed to fill gaps in its neurology pipeline as it prepares to lose exclusivity for its top global product.

Business Strategies M & A

Pipeline Watch: Phase III Progress With Nimotuzumab, Solriamfetol, And Upadacitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Approvals Research & Development
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sumitomo Chemical Co.
  • Senior Management
  • Patricia S Andrews, CEO
    David S Leggett, PhD, VP, COO
    Edgar Braendle, MD, PhD, EVP, Head, R&D & CMO
  • Contact Info
  • Boston Biomedical Inc.
    Phone: (781) 278-0900
    333 Providence Hwy.
    Norwood, MA 02062
    USA
UsernamePublicRestriction

Register